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New roles for the major human 3'–5' exonuclease TREX1 in human disease
David Kavanagh,1 Dirk Spitzer,2 Parul H. Kothari,2 Aisha Shaikh,2 M. Kathryn Liszewski,2 Anna Richards3 and John P.
Atkinson2,*
1Institute of Human Genetics; Newcastle University; Newcastle upon Tyne, United Kingdom; 2Division of Rheumatology; Department of Medicine; Washington University School
of Medicine; St Louis, Missouri USA; 3Department of Renal Medicine; University of Edinburgh; Royal Infirmary; Little France, Edinburgh United Kingdom

Abbreviations: AGS, aicardi-goutières syndrome; SLE, systemic lupus erythematosus; FCL, familial chilblain lupus; RVCL, retinal
vasculopathy and cerebral leukodystrophy; CRV, cerebroretinal vasculopathy; HVR, hereditary vascular retinopathy; HERNS, hereditary
endotheliopathy, retinopathy and nephropathy; HSA, hereditary systemic angiopathy
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impair its exonuclease activity.3 FCL is a rare, inherited form of lupus
with prominent skin manifestations in which autosomal dominant
mutations in TREX1 that decrease exonuclease activity have been
described.4,5 Mutations in TREX1 have also been identified in ~3%
of patients with SLE, a complex disease with diverse, systemic manifestations predominantly affecting women of child-bearing age.6
The goal of this review is to collate the existing information on these
genetically related diseases with an emphasis on how the mutations
in TREX1 lead to the disease state.

ON

Aicardi-Goutières syndrome (AGS), Systemic Lupus
Erythematosus (SLE), Familial Chilblain Lupus (FCL) and
Retinal Vasculopathy and Cerebral Leukodystrophy (RVCL) {a
new term encompassing three independently described conditions with a common etiology—Cerebroretinal Vasculopathy
(CRV), Hereditary Vascular Retinopathy (HVR) and Hereditary
Endotheliopathy, Retinopathy and Nephropathy (HERNS)}—
have previously been regarded as distinct entities. However,
recent genetic analysis has demonstrated that each of these
diseases maps to chromosome 3p21 and can be caused by mutations in TREX1, the major human 3'–5' exonuclease. In this
review, we discuss the putative functions of TREX1 in relationship to the clinical, genetic and functional characteristics of each
of these conditions.
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Recently, mutations in the ubiquitously expressed human 3'–5'
exonuclease TREX1 (DNase III) have been linked to four apparently
independent diseases. In the case of Cerebroretinal Vasculopathy
(CRV), Hereditary Endotheliopathy, Retinopathy and Nephropathy
(HERNS) and Hereditary Vascular Retinopathy (HVR), a common
etiology was first suspected based on clinical similarities and further
supported when all showed evidence of linkage to a single locus on
chromosome 3p21.1 We now know that these diseases consolidate
to a single autosomal dominant inherited entity named Retinal
Vasculopathy and Cerebral Leukodystrophy (RVCL) in which there
are mutations affecting the carboxyl-terminus of TREX1.2 The other
three diseases, Aicardi-Goutières syndrome (AGS), Systemic Lupus
Erythematosus (SLE) and Familial Chilblain Lupus (FCL), share
some clinical similarity but appear to be distinct clinical conditions.
AGS, a severe, usually lethal disease, resembling an intrauterine viral
infection has been associated with recessive mutations in TREX1 that
*Correspondence to: John P. Atkinson; Department of Medicine; Division of
Rheumatology; Washington University School of Medicine; St. Louis, Missouri 63110
USA; Tel.: 001.314.362.8391; Email: jatkinso@im.wustl.edu
Submitted: 04/12/08; Accepted: 04/16/08
Previously published online as a Cell Cycle E-publication:
http://www.landesbioscience.com/journals/cc/article/6162
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Deoxyribonucleases (DNA nucleases) are essential to maintain
genome stability and are involved in processes such as DNA replication, repair and recombination.7 These enzymes can be divided
into two classes: endonucleases that hydrolyse the deoxyribose phosphodiester backbone within the DNA strand and exonucleases that
hydrolyse the phosphodiester bonds at the DNA ends. Nucleases
have selective affinity for single-stranded (ss) or double-stranded (ds)
DNA. They differ in their mode of action (5'–3' or 3'–5' direction)
and their main reaction products (5' mono- or dinucleotides and 3'
mononucleotides).8
DNA replication during mitosis follows a complex sequence of
events in which polymerases are responsible for the accurate duplication of the parental chromosomes. In mammalian cells, the estimated
spontaneous mutation rate is 10-10–10-12 per cell division.9 This
is, however, orders of magnitudes lower than the mutation rate of
DNA polymerases such as Pol α and Pol β (10-4–10-5).10 They are
not accurate enough to replicate our 3 billion base pair genome
without deleterious consequences. Such a high mutation rate would
be incompatible with life and is why some DNA polymerases (e.g.,
Pols γ, δ and ε) contain additional 3'–5' exonuclease activity. This
“intrinsic” proofreading activity enables the polymerases to enhance
the accuracy of DNA synthesis by removing incorrectly incorporated
nucleotides before the replication process is reinitiated.
A second class of exonucleases is considered autonomous. These
enzymes can hydrolyse their target sequences independently and
may also assist DNA polymerases lacking this activity (e.g., Pol
α) to increase their fidelity under normal conditions or in cases
of genotoxic cell stress.9 TREX1 is the most abundant DNA 3'–5'
exonuclease in mammalian cells.8,11
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Figure 1. Schematic diagram of the TREX1 protein structure with sites of mutations associated with human disease. Numbers for each mutation correspond
with those listed in Table 1. Regions I, II and III represent the exonuclease domains (Exo I–III). Region P represents the polyproline II helix (PPII). Region TMD
represents the putative transmembrane domain.
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TREX1 (former DNase III, Three prime Repair EXonuclease)
was identified in 1999 by Hoss et al.12 and Mazur and Perrino.13
The gene for TREX1 consists of a single exon and encodes a protein
of 314 amino acids. Sequence homology places TREX1 in the DnaQ
3'–5' exonuclease family.14-16 The characteristic features of this
family of exonucleases are three conserved sequence motifs, Exo I,
Exo II and Exo III, which form the active site of the enzyme14-16
(Fig. 1). Recent crystal structures of murine Trex1 with DNA17
demonstrate a dimer with the active sites on opposing surfaces,
allowing the potential for concurrent interaction with two 3' DNA
ends. These structures demonstrate close similarity with another
DnaQ 3'–5' exonuclease, the Escherichia coli DNA polymerase I.
In addition to these three exonuclease motifs, TREX1 has a highly
hydrophobic carboxyl-terminal region which is predicted to form a
transmembrane helix.6,18 Deletion mutagenesis has demonstrated
that this region is important in intracellular localization but has no
role in the catalytic function.2,6 The TREX1 protein also contains a
proline-rich sequence (PPII helix).17,18 This motif has been reported
to play a crucial role in protein-protein interactions, specifically
with Src homology 3, WW and EVH1 domains.19 The structure of
TREX1 indicates that the PPII helix is surface exposed and available
for protein interactions.17,18 This has been hypothesized to account
for the interaction of TREX1 with the SET complex17 (see below).

an autoimmune-like inflammatory myocarditis leading to a dilated
cardiomyopathy and a dramatically reduced lifespan.22
Another role for TREX1 has been suggested by its association
with the SET complex.23 This protein complex is involved in
granzyme A-mediated cell death, a caspase-independent pathway
which involves ssDNA damage. The killer lymphocyte associated
protease, granzyme A, causes mitochondrial damage and superoxide
generation that induces nuclear translocation of the SET complex.
It then cleaves the NM23-H1 inhibitor, SET, freeing NM23-H1 to
make a ssDNA cut (introduces a DNA nick) that is then extended
by TREX1. Cells with silenced TREX1 are relatively resistant to
apoptotic cell death but remain sensitive to the caspase-activating
granzyme B.23
A role for TREX1 in cell homeostasis has recently been described
by Yang and colleagues.24 They demonstrated that TREX1 deficiency results in constitutive activation of the ATM-dependent
DNA damage checkpoint. This results in impaired G1/S transition
in Trex1-deficient cells. Additionally, a 60–65 bp ssDNA species
accumulates in the cytoplasm. Importantly, similar phenotypic
observations were obtained from both Trex1-deficient mouse cells as
well as from patient cells homozygous for a non-functional mutant
form of the protein. These roles of TREX1 have been postulated to
be critical in controlling autoimmunity24,25 and will be discussed
later.
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Elucidation of the definitive in vivo function of TREX1 has
proved problematic. TREX1 is an autonomous non-processive 3'–5'
DNA-specific exonuclease with a preference for ssDNA or mispaired
3' termini.12,13,20,21 Further analysis has suggested that, unusual for
an exonuclease, TREX1 has a significant preference for particular
DNA sequences and that this correlates with exonuclease activity.18
This exonuclease function, in addition to slight homology with
known editing enzymes, suggests that it may serve a DNA-editing
role in DNA replication or gap filling during DNA repair. However,
this has not been borne out by an increase in spontaneous mutation rate or a higher cancer incidence in the Trex1 knockout mouse
as would have been predicted if TREX1 served an obligatory role
of editing mismatched 3' termini generated during DNA repair
or DNA replication. Instead, the Trex1 knockout mouse displayed
www.landesbioscience.com

TREX1 versus TREX2
TREX1 has a homologue, TREX2, which has ~40% amino acid
sequence identity with TREX1.13,26 TREX2 is also an autonomous
DNA 3'–5' exonuclease,13,26 important for cell proliferation.26
TREX2 lacks the ~75 amino acid carboxyl-terminal hydrophobic
domain found in TREX1. This region is responsible for intracellular localization and contains the non-repetitive proline-rich region
which plays a crucial role in protein-protein interactions. TREX2
contains a conserved DNA binding loop positioned adjacent to the
active site that has a sequence distinct from the corresponding loop
in the TREX1 enzyme. These differences suggest non-overlapping
physiological roles for these proteins.

Cell Cycle
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Familial chilblain lupus (FCL, OMIM 610448) is a rare cutaneous
form of SLE. It is an autosomal dominant disease in which affected
members present in early childhood with painful bluish-red inflammatory cutaneous lesions, typically on fingers, toes, ear helices, nose
and cheeks. These lesions worsen with cold or wet exposure. They
usually heal without scarring but may ulcerate leading to atrophic
and hypopigmented skin and, in severe cases, to destruction of interphalangeal joints and distal toes.4,5,43 Some affected individuals also
have antinuclear antibodies and immune complexes.4,5,43 Progression
to SLE is documented in 18% of individuals with chilblain lupus44
but has not yet been described in individuals with FCL.
A SNP-based genome-wide linkage analysis mapped FCL to
chromosome 3p and a subsequent haplotype analysis narrowed
the locus to 3p21-14, an area that includes the gene for TREX1.4
Although FCL is not associated with neurological pathology, there is
some overlap with AGS in which some affected individuals develop
chilblains and autoantibodies. Hence, TREX1 was considered a plausible candidate gene and sequencing of affected individuals revealed
several mutations.
Rice et al.5 reported a family with compound heterozygous
mutations in three siblings (c.375dupT/F17S), though the disease
segregated with only the c.375dupT mutation which was assumed
to be inherited from the unstudied affected father. The c.375dupT
mutation resulted in a truncated protein missing the last 188 amino
acids, which would be predicted to be functionally significant. The
mother carrying the F17S mutation was unaffected. This change is
assumed to be a rare polymorphism. Exonuclease assays on lymphoblastoid cell lines derived from the affected individuals demonstrate
decreased enzymatic activity.5
Lee-Kirsch et al.43 described a heterozygous mutation (D18N) in
a family with FCL. Functional analysis of this mutation revealed a
loss of exonuclease function. Further analysis demonstrated reduced
sensitivity to granzyme A-mediated cell death in patient-derived
lymphoblastoid cell lines.
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In 1984, the autosomal recessive Aicardi-Goutières syndrome
(AGS)(OMIM 225750) was first described in eight children from
five unrelated families who developed progressive encephalopathy of
early onset, brain atrophy, demyelination, basal ganglia calcifications
and chronic cerebrospinal fluid (CSF) lymphocytosis.27 These clinical findings mimic those observed with intrauterine infections but
evaluation for an infectious etiology was negative. Affected children
typically present before 4 months of age with failure to progress in
motor and social skills while one-third of cases present later, between
4 and 12 months of age, with loss of previously acquired motor and
mental skills.28 Neurological manifestations also include spasticity
and an acquired microcephaly. Extra-neurological features observed
in a subset of patients include hepatosplenomegaly, anemia, thrombocytopenia, elevated liver transaminases and chilblains (ulcerating
lesions on fingers, toes or ear lobes).28 Due to the similarity between
AGS and intrauterine infection, levels of interferon α (IFNα) were
measured and found to be elevated in the CSF of affected infants.29
Two other familial diseases, the microcephaly and intracranial
calcification syndrome (MICS)30,31 and Cree Indian encephalitis,32
which were initially described as separate disorders, have considerable overlap with AGS. All three are inherited as autosomal recessive
diseases, can have increased levels of IFNα in the CSF, and manifest
various extra-neurological findings such as hepatosplenomegaly,
thrombocytopenia, elevated liver transaminases and chilblains.33,34
Furthermore, Cree encephalitis has been found to be allelic with
AGS.3,34 Thus, AGS, MICS and Cree encephalitis appear to represent the same disorder.
Several cases in the literature have also reported an overlap
between AGS and infantile systemic lupus erythematosus (SLE).35-37
In addition to findings compatible with the diagnosis of AGS,
the affected children had autoantibodies typically found in lupus
with antigenic specificity for cardiolipin, ssDNA, dsDNA and
RNA-protein complexes. Notably, neuro-lupus has also been associated with increased levels of IFNα in the CSF despite being a
non-infectious disorder.38
The recent elucidation of the genetic basis for AGS provides a rationale for its clinical diversity. TREX1 mutations were first demonstrated
to cause AGS by Crow et al. (AGS1, OMIM 225750).3 Functional
characterization of only a few AGS associated TREX1 mutations have
been performed3,5,13 (see Table 1); however, in the recessive mutations
examined, a defect in exonuclease activity was demonstrated. This is
further supported by Yang et al., who have demonstrated the presence
of ssDNA in Trex1-null cells, findings also seen in AGS patient cells
carrying homozygous mutations in TREX1.24
Although AGS is classically inherited in an autosomal recessive
manner, there is an isolated report of an individual with an autosomal
dominant form of the disease caused by a TREX1 mutation (AGS5;
OMIM 610905).5 This individual possessed a D200N mutation
which, on functional analysis, demonstrated close to normal levels of
exonuclease activity. Although the mechanism of action remains to
be established, it is proposed that this mutant alters the specificity of
TREX1 or interferes with protein-protein interactions.
In addition to mutations in TREX1, mutations in three other
genes [RNASEH2A (AGS4, OMIM 606034); RNASEH2B (AGS2,
OMIM 610326); RNASEH2C (AGS3, OMIM 610330)] have
been reported to cause AGS.39 RNase H2 is the principal source of

ribonuclease activity in the cell,40,41 however, the mechanism through
which a reduction in ribonuclease activity leads to disease remains
speculative. Increased amounts of RNA-DNA hybrids stimulating
an innate immune response with overproduction of IFNα have been
hypothesized. In addition to these four causative genes, additional
genes responsible for AGS are suggested by a cohort of affected individuals in whom mutations have not been identified.42
Analysis of a large cohort of AGS has revealed genotype:phenotype correlations in the disease.42 For instance, individuals with
TREX1 mutations tend to present at birth while individuals with
mutations in RNASEH2B present later. AGS caused by RNASEH2B
mutations also seems to have a milder phenotype with a lower
mortality and relatively preserved intellectual function.42
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Retinal Vasculopathy and Cerebral Leukodystrophy
Cerebroretinal Vasculopathy (CRV) is an inherited disorder first
described by Grand et al., in 1988.45 It begins in middle age with
predominant central nervous system, especially retinal, involvement.
Study of eight patients spanning three generations in the initial
pedigree showed 100% penetrance with an autosomal dominant
mode of inheritance. The disease manifestations begin during the
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Table 1

TREX1 mutations found in human disease

#

Nucleotide change

Amino acid change

Exonuclease Function

Intracellular Localization

Disease

Segregation

Reference

1

520→A

D18N

Decreased

NT

FCL

Het

43

2

58_59insG

E20fs

NT

NT

AGS

Hom

3

3

212_2l3dupTG

A72fs

NT

NT

AGS

Hom

42

4

341G→A

R114H

Decreased

Perinuclear

AGS

Hom

2, 3

4

341G→A

R114H

Decreased

Perinuclear

SLE

Het

2, 6

5

365T→C

V122A

NT

NT

AGS

Hom

42

6

366_368dupGGC

Al24ins

NT

NT

AGS

Hom

42

7

375dupT

G126fs

Decreased

NT

FCL

Het

5

8

393_408dup

E137fs

NT

NT

AGS

Hom

42

397delC

L133fs

NT

NT

AGS

Hom

42

10

473C→T

A158V

NT

NT

SLE

Het

6

11

490C→T

R164X

NT

NT

12

500delG

S167fs

NT

NT

UT
E

.

9

AGS

Hom

3

AGS

Hom

42

598G→A

D200N

Normal

NT

AGS

Het

5

14

600_60linsGAT

D201ins

Decreased

NT

AGS

Comp het, R114H

3, 17

IST
RIB

13

V201D

Decreased

NT

AGS

Hom

3, 17

609_662dup

A203ins

NT

NT

AGS

Hom

42

17

625_628dupCAGT

W210fs

NT

NT

AGS

42

18

634delC

P212fs

NT

Cytoplasm

SLE

Het

6

19

703_704insG

V235fs

Normal

20

706_707insA

T236fs

Normal

21

679G→A

G227S

NT

22

720G→C

R240S

NT

A247P
T249fs

812_8l3insAA

P272fs

850_851insA

R284fs

27

857_858insG

R287fs

28

868_885del

P290del

914A→G
917G→C

33

979delC

2
2

NT

SLE

Comp het, A247P?

6

NT

SLE

Het

6

NT

NT

SLE

Comp het, G227S?

6

NT

Nucleus/Cytoplasm

RVCL

Het

2

Normal

Nucleus

SLE

Het

6

NT

NT

RVCL

Het

2

NT

Nucleus/Cytoplasm

RVCL

Het

2

NT

NT

AGS

Hom

42

BIO
P290L

NT

NT

SLE

Het

6

NT

NT

AGS

Hom

42

Y305C

NT

NT

SLE

Het

6

G306A

NT

NT

SLE

Het

6

3' UTR

NT

NT

SLE

Het

6

LA

31
32

Het
Het

T303P

ES

869C→T
907A→C

ND

29
30

RVCL

RVCL

SC

25
26

Nucleus/Cytoplasm

Nucleus/Cytoplasm

.D

739G→C
742_745dupGTCA

Hom

IEN
CE

23
24
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602T→A
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Numbers correspond to those shown in Figure 1. NT: Not tested.
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fourth or fifth decade and there is 100% mortality over a 5 to 10
year period secondary to progressive neurological decline. Typical
ophthalmologic findings on retinal fluorescein angiograms are capillary dropouts, particularly in the macular region, leading to loss of
central vision, prominent juxta-foveolar capillary obliteration and
telangiectasias. Neurological manifestations commonly observed
were transient ischemic attacks and strokes with motor and sensory
loss, cognitive dysfunction, headaches, personality disorders, depression and anxiety. CT scans often show mass lesions with displacement
of the surrounding structures and central contrast enhancement
commonly in the frontoparietal region. Histopathology demonstrates coagulative necrosis secondary to an obliterative vasculopathy
and minimal inflammatory infiltrate (“as if the brain had been radiated”). Autopsies demonstrate involvement of pons, cerebellum and
basal ganglia in addition to the frontoparietal region.45 The CRV
www.landesbioscience.com

family has now been followed for over two decades (Atkinson JP,
unpublished data). Hepatic and renal findings are not as clinically
prominent as those seen in the nervous system but noteworthy
from a clinical point of view in about one-third. Elevation of liver
alkaline phosphatase is common and at autopsy, nodular regenerative hyperplasia is found. Renal dysfunction of a glomerular origin
with proteinuria and elevation of creatinine is also observed. Renal
histopathology is most suggestive of accelerated arteriolonephrosclerosis. Small vessel type gastrointestinal bleeding is also seen. Taken
together, these data implicate small vessel vasculopathy leading to
premature infarction and necrosis of the tissue.
A smaller family of Ashkenazi Jewish ancestry was next reported,
in which the affected individuals had evidence of retinal vasculopathy on fluorescein angiograms and periventricular white matter
lesions on brain MRI.46 No follow-up on this family was possible.
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grouped together as Retinal Vasculopathy
with Cerebral Leukodystrophy (RVCL,
OMIM 192315) and the causative gene
mutations were identified as carboxylterminus frame shifts in TREX1.2 These
mutant TREX1 forms (lacking their
native carboxyl-termini), no longer
localize to their usual perinuclear site.2
Instead, they are now apparently capable
of freely diffusing throughout the cell
(Fig. 2C and corresponding intensity
profiles D). Their distribution profile
is indistinguishable from that of the
fluorescent protein alone (Fig. 2A).
Importantly, the exonuclease activity
of these proteins is fully preserved. In
contrast, fluorescent protein-tagged wild
type TREX1 or TREX1 with deficient
enzymatic activity are concentrated
in the expected perinuclear space and
Figure 2. Functional consequences of TREX1 mutations associated with RVCL. Confocal microscopy of
HEK293T cells showing transiently expressed yellow fluorescent protein (eYFP)-tagged TREX1 proteins
are not detectable in the cytoplasm or
(green), TOPRO3 staining of nuclei (red), and the overlay for eYFP alone (A), wild-type TREX1 (B), and
nucleus (Fig. 2B).
the CRV mutant form of TREX1 (C) as well as the corresponding intensity profile for each across region of
A recent report by Winkler et
drawn arrow (D).
al., details a familial disease they call
Hereditary Systemic Angiopathy (HSA)
However, in the original report45 there was also a patient of which bears a remarkable resemblance to RVCL.53 The affected
Ashkenazi Jewish origin with probable CRV whose disease has individuals present in the fourth to fifth decade with visual
now been confirmed genetically.2 In 1999 and 2000, Weil et al.,47 disturbances, migraine-like headaches, and neurological symptoms
and Niedermayer et al.,48 respectively reported two other families including seizures, motor paresis and cognitive decline. As the
disease progresses, some develop renal and/or hepatic dysfunction.
thought to have CRV.
In 1990, Storimans et al. published a preliminary report describing Furthermore, the pathologic findings correlate with those seen in
Hereditary Vascular Retinopathy (HVR), a syndrome of retinal RVCL. Although the authors had included CRV, HVR and HERNS
vasculopathy, migraines and Raynaud’s phenomena in a Dutch in their differential diagnosis as separate entities, it is now clear that
kindred.49 It was further described by Terwindt et al., in 1998.50 As all three represent the spectrum encompassing RVCL and HSA
initially reported, these patients did not appear to have pseudotu- would also seem to fall within that spectrum.
mors, renal dysfunction or shortened life expectancy similar to that
seen in CRV patients. Furthermore, the visual acuity in these patients Systemic Lupus Erythematosus and Sjogren’s Syndrome
was largely preserved due to predominant peripheral retinal involveSystemic Lupus Erythematosus (SLE) (OMIM152700) and
ment.50 However, further follow-up indicates that the clinical course Sjögren’s syndrome (SS) (OMIM 270150) are prototypes of autois similar to the CRV and HERNS kindreds (see below; from Arn immune diseases because of the generation of a wide array of
MJM van den Maagdenberg to JPA, personal communication).
autoantibodies. SLE is clinically very heterogeneous and linkage
In 1997, Jen et al., described a Chinese American family with studies and candidate gene studies have suggested many genes are
11 affected members spanning three generations who manifested involved in its pathogenesis (Table 1).54,55
a CRV-like illness.51 This group named the disease Hereditary
As with AGS, SLE and SS are notable for the generation of antiEndotheliopathy with Retinopathy, Nephropathy and Stroke nuclear antibodies and an IFNα activation signature. Rice et al.
(HERNS). Ultrastructural studies showed distinctive multilami- reported that at least one parent of a patient with AGS had SLE.5
nated vascular basement membrane in the brain and other tissues, As a result of these similarities and the autoimmune phenotype of
including the kidney, gastrointestinal tract and skin. Genetic analysis the Trex1 knockout mouse, Lee-Kirsch et al. sequenced the coding
ruled out linkage to the cerebral autosomal dominant arteriopathy regions of TREX1 in lupus cohorts from the United Kingdom,
with subcortical infarcts and leukoencephalopathy (CADASIL) locus Germany and Finland and discovered mutations in ~3% of indion chromosome 19.51
viduals with SLE.6 Subsequent work also demonstrated TREX1
A whole genome screen in the extended Dutch family found mutations in individuals with SS.6
probable linkage to 3p21.1-p21.3.1 Genetic analysis of patients
Mutations in SLE were seen throughout the TREX1 gene.
from the CRV and HERNS kindreds demonstrated linkage to the Although functional analysis of the missense changes was not
same region. In 2005, Cohn et al., reported a family diagnosed with performed, at least one of the mutants described in SLE had been
HERNS and prominent peripheral retinal involvement who also previously reported in AGS, R114H. Functional assessment of this
mapped to 3p21.1-p21.3.52 In 2007, CRV, HERNS and HVR were mutant demonstrated decreased exonuclease activity, establishing
1722
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This review has described four independent conditions found
to have a common underlying etiology through mutations in the
major mammalian autonomous 3'–5' exonuclease TREX1. Although
mutations in TREX1 are connected to all four conditions, there are
differences with respect to the functional changes which allow some
genotype:phenotype correlations to be defined (Table 2).
Homozygous TREX1 mutations cause the typical autosomal recessive form of AGS. Where functional analysis has been performed,
these mutations result in decreased exonuclease function.3,5,17
Only one documented case of autosomal dominant AGS has been
described in the literature. Although the reported mutation does not
alter exonuclease activity in vitro, it may be non-functional in vivo.5
FCL is associated with heterozygous mutations in TREX1. In all
individuals examined these mutations result in reduced exonuclease
activity.5,43 Some heterozygous parents of children with AGS have
been reported to present with chilblains following cold exposure.5
Although a much milder condition than AGS, FCL has sufficient
phenotypic overlap (chilblain-like lesions and antinuclear antibodies)
to suggest that the difference in these diseases may be a gene dosage
effect. Therefore it appears that a partial loss of exonuclease activity
is sufficient to cause FCL
RVCL is also associated with heterozygous mutations in TREX1.
In contrast to the heterozygous mutations characterizing FCL, all
the mutations described are in the carboxyl-terminus of TREX1
and disrupt the predicted transmembrane domain.6,18 They do
not diminish the enzymatic function of TREX1 but alter its intracellular localization.2 We speculate that the phenotype seen in RVCL
is due to loss of the carboxyl-terminus which results in dissemination
of TREX1 throughout the cell. We hypothesize that this leads to a
detrimental gain-of-function phenotype. Alternatively, the mutations
could just result in insufficient quantities of TREX1 in the correct
location to fulfill its physiological role. How the latter explanation
would fit with the phenotypic differences seen between RVCL and
FCL is unclear.
Heterozygous mutations in TREX1 have also been identified in a
small number of SLE patients. Unlike the mutations in FCL which
disrupt exonuclease function and RVCL which disrupt intracellular
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localization, the mutations observed in SLE are diverse. Some mutations disrupt exonuclease activity, others result in altered intracellular
localization, and many are of unknown significance. SLE is a complex
clinical disease and heterozygous mutations in TREX1 appear to
account for only ~3% of cases.6 Detailed phenotypic examination of
these individuals may result in a clearer understanding of the differences among RVCL, AGS and FCL.
These conditions also provide a window into a better understanding of the in vivo roles of TREX1. In the 10 years since TREX1
was discovered, there has been much speculation on the cellular
function of this enzyme. Based on its involvement in these human
diseases and from knockout animal studies, it seems that TREX1
does not have a requisite role in DNA repair. In contrast, it appears
to be involved in the regulation of immunity through several nonmutually exclusive pathways.
Yang et al., have recently demonstrated that TREX1-deficient cells
accumulate ~60 bp ssDNA species in the cytoplasm.24 Such DNA
intermediates are not exclusively generated during DNA replication.
For example, DNA viruses and retroviruses are additional sources of
DNA species that could accumulate if a degrading enzyme is lacking.
In the absence of TREX1, the DNA intermediates required for the
viral replication cycle could accumulate and become immunostimulatory. A similar scenario applies to active endogeneous retroviruses
(and retrotransposons) residing in the human genome.25
Cell surveillance for viral DNA and RNA is in the form of
Toll-like receptors, some of which reside in the cytoplasm.57 Under
normal physiological conditions host DNA is sequestered from these
receptors in the nucleus or mitochondria. It is possible that the cytoplasmic ssDNA plays a pathogenic role by mimicking viral DNA
and stimulating these receptors. This will result in the production of
antiviral cytokines including IFNα.
It is intriguing that both SLE and AGS are associated with high
levels of IFNα. SLE has long been associated with high serum
IFNα levels58 and these levels correlate with disease activity and
severity.58-60 Evidence that the raised IFNα levels may be important
in disease pathogenesis comes from individuals treated with IFNα
for malignancies and chronic hepatitis C who have been seen to
develop autoimmune diseases including SLE.61,62 Mouse models of
SLE also lend weight to a pathogenic role for IFNα. Administration
of IFNα, either exogenously,63,64 through an adenovirus vector,65
or by injection of IFNα-inducing agents66 in mouse models of
lupus have demonstrated increased severity of disease. Additionally,
some lupus-prone mice lacking the Type I interferon receptor have a
milder disease phenotype.67,68 A role for IFNα in the pathogenesis
of AGS is suggested by the reproduction of the neuropathology in
transgenic mice with astrocytes chronically producing IFNα who
develop a progressive inflammatory encephalopathy, calcifications
and neurodegeneration.69
Although no studies have examined IFNα in RVCL, several pieces
of evidence may suggest such an association. Although distinct from
the retinopathy of RVCL, there is a retinopathy associated with interferon that is characterized by cotton wool spots, retinal hemorrhages
and microaneurysms.70-74 Migraine and Raynaud’s phenomenon
are also side-effects of IFNα treatment and are seen in RVCL. If the
pathogenic role of IFNα in RVCL can be confirmed, then this would
at last provide some hope for a condition which currently has a grim
prognosis. Chloroquine and glucocorticoids have been used in SLE
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that at least some of the SLE mutants affect enzymatic function.36
Other missense mutants, however, lie outside the catalytic domain
and their functional significance remains unclear.6
Two frameshift mutations were also observed in SLE. Analogous
to the mutations reported in RVCL, these mutations would not be
predicted to disrupt enzymatic function. Functional analysis of one
of these mutants, D272fs, failed to show any major enzymatic deficiency; however, as with all mutations seen in RVCL, the frameshift
mutations in SLE also altered subcellular localization. Interestingly,
the two mutants observed in SLE had different intracellular distributions: the P212fs mutant distributed throughout the cytoplasm in
endosomal vesicles while the D272fs mutant was almost exclusively
localized within the nucleus, possibly in association with subnuclear
organelles.6
In a recent study by Hur et al., although no conclusive association
between TREX1 polymorphisms and SLE was demonstrated, certain
TREX1 polymorphisms were protective against the development of
autoantibodies.56
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Table 2 Clinical, pathological and laboratory features of diseases associated with TREX1 mutations
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*One autosomal dominant case reported;4 ANA, antinuclear antibodies; APLS, antiphospholipid; CSF, cerebrospinal fluid; GI, gastrointestinal.
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and inhibit IFNα production75 and the IFN signature76 respectively.
Humanized monoclonal anti-IFNα antibodies77 and soluble IFNα
receptors78 may also become therapeutic options. However, further
investigation is required to confirm a pathogenic role for IFNα in
RVCL as IFNα may not be the only link between TREX1 mutations
and immunity.
Yang et al. also demonstrated that Trex1-deficient cells had constitutive activation of the ATM-dependent DNA-damage checkpoint
resulting in impaired G1/S transition.24 This has been hypothesized
to impair T-lymphocyte development which may reduce their
ability to regulate self tolerance.25 TREX1 has also been shown to
be involved in granzyme A-mediated cell death. Granzyme A is
released by cytotoxic T-cells and NK-cells. It has been demonstrated
that granzyme A-mediated cell death is impaired in FCL43 which
may lead to the retention of autoreactive lymphocytes resulting in
disease.
Thus, the last two years have seen the remarkable discovery
of mutations in one gene, TREX1, which are responsible for four
distinct clinical diseases. They have, however, areas of clinical and
genetic overlap which point to a common pathological mechanism. Further definition of the physiological and pathological role
of TREX1 will hopefully lead to treatment advances for all these
conditions.

1724

References
1. Ophoff RA, DeYoung J, Service SK, et al. Hereditary vascular retinopathy, cerebroretinal
vasculopathy and hereditary endotheliopathy with retinopathy, nephropathy and stroke
map to a single locus on chromosome 3p21.1-p21.3. Am J Hum Genet 2001; 69:447-53.
2. Richards A, van den Maagdenberg AM, Jen JC, et al. Truncations in the carboxyl-terminus
of human 3'–5' DNA exonuclear TREX1 cause autosomal dominant retinal vasculopathy
with cerebral leukodystrophy. Nat Genet 2007; 39:1068-70.
3. Crow YJ, Hayward BE, Parmar R, et al. Mutations in the gene encoding the 3’–5’ DNA
exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus. Nat Genet 2006;
38:917-20.
4. Lee-Kirsch MA, Gong M, Schulz H, et al. Familial chilblain lupus, a monogenic form of cutaneous lupus erythematosus, maps to chromosome 3p. Am J Hum Genet 2006; 79:731-7.
5. Rice G, Newman WG, Dean J, et al. Heterozygous mutations in TREX1 cause familial
Chilblain lupus and dominant Aicardi-Goutieres syndrome. Am J Hum Genet 2007;
80:811-5.
6. Lee-Kirsch MA, Gong M, Chowdhury D, et al. Mutations in the gene encoding the 3'–5'
DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet
2007; 39:1065-7.
7. Hubscher U, Maga G, Spadari S. Eukaryotic DNA polymerases. Annu Rev Biochem 2002;
71:133-63.
8. Lindahl T, Gally JA, Edelman GM. Properties of deoxyribonuclease 3 from mammalian
tissues. J Biol Chem 1969; 244:5014-9.
9. Shevelev IV, Hubscher U. The 3'–5' exonucleases. Nat Rev Mol Cell Biol 2002; 3:364-76.
10. Drake JW, Charlesworth B, Charlesworth D, Crow JF. Rates of spontaneous mutation.
Genetics 1998; 148:1667-86.
11. Lindahl T. Excision of pyrimidine dimers from ultraviolet-irradiated DNA by exonucleases
from mammalian cells. Eur J Biochem 1971; 18:407-14.
12. Hoss M, Robins P, Naven TJ, Pappin DJ, Sgouros J, Lindahl T. A human DNA editing enzyme homologous to the Escherichia coli DnaQ/MutD protein. EMBO J 1999;
18:3868-75.
13. Mazur DJ, Perrino FW. Identification and expression of the TREX1 and TREX2 cDNA
sequences encoding mammalian 3’→5’ exonucleases. J Biol Chem 1999; 274:19655-60.

Cell Cycle

2008; Vol. 7 Issue 12

TREX1 in human diseases

OT
D

IST
RIB

UT
E

.

47. Weil S, Reifenberger G, Dudel C, Yousry TA, Schriever S, Noachtar S. Cerebroretinal vasculopathy mimicking a brain tumor: a case of a rare hereditary syndrome. Neurology 1999;
53:629-31.
48. Niedermayer I, Graf N, Schmidbauer J, Reiche W. Cerebroretinal vasculopathy mimicking
a brain tumor. Neurology 2000; 54:1878-9.
49. Storimans CW, Oosterhuis JA, van Schooneveld MJ, Bos PJ, Maaswinkel-Mooy PD.
Familial vascular retinopathy. A preliminary report. Doc Ophthalmol 1990; 75:259-61.
50. Terwindt GM, Haan J, Ophoff RA, et al. Clinical and genetic analysis of a large Dutch family with autosomal dominant vascular retinopathy, migraine and Raynaud’s phenomenon.
Brain 1998; 121:303-16.
51. Jen J, Cohen AH, Yue Q, et al. Hereditary endotheliopathy with retinopathy, nephropathy
and stroke (HERNS). Neurology 1997; 49:1322-30.
52. Cohn AC, Kotschet K, Veitch A, Delatycki MB, McCombe MF. Novel ophthalmological
features in hereditary endotheliopathy with retinopathy, nephropathy and stroke syndrome.
Clinical & Experimental Ophthalmology 2005; 33:181-3.
53. Winkler DT, Lyrer P, Probst A, et al. Hereditary Systemic Angiopathy (HSA) with cerebral calcifications, retinopathy, progressive nephropathy and hepatopathy. J Neurol 2008;
255:77-88.
54. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008; 358:929-39.
55. Crow MK. Collaborations, genetic associations and lupus erythematosus. N Engl J Med
2008; 358:956-61.
56. Hur JW, Sung YK, Shin HD, Park BL, Cheong HS, Bae SC. TREX1 polymorphisms associated with autoantibodies in patients with systemic lupus erythematosus. Rheumatol Int
2007.
57. Unterholzner L, Bowie AG. The interplay between viruses and innate immune signaling:
recent insights and therapeutic opportunities. Biochem Pharmacol 2008; 75:589-602.
58. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979; 301:5-8.
59. Bengtsson AA, Sturfelt G, Truedsson L, et al. Activation of type I interferon system in
systemic lupus erythematosus correlates with disease activity but not with antiretroviral
antibodies. Lupus 2000; 9:664-71.
60. Dall’era MC, Cardarelli PM, Preston BT, Witte A, Davis JC Jr. Type I interferon correlates
with serological and clinical manifestations of SLE. Ann Rheum Dis 2005; 64:1692-7.
61. Gota C, Calabrese L. Induction of clinical autoimmune disease by therapeutic interferonalpha. Autoimmunity 2003; 36:511-8.
62. Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for
malignant carcinoid tumors. Ann Intern Med 1991; 115:178-83.
63. Heremans H, Billiau A, Colombatti A, Hilgers J, de Somer P. Interferon treatment of NZB
mice: accelerated progression of autoimmune disease. Infect Immun 1978; 21:925-30.
64. Adam C, Thoua Y, Ronco P, Verroust P, Tovey M, Morel-Maroger L. The effect of exogenous interferon: acceleration of autoimmune and renal diseases in (NZB/W) F1 mice. Clin
Exp Immunol 1980; 40:373-82.
65. Mathian A, Weinberg A, Gallegos M, Banchereau J, Koutouzov S. IFNalpha induces early
lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in
BALB/c mice. J Immunol 2005; 174:2499-506.
66. Walker SE. Accelerated mortality in young NZB/NZW mice treated with the interferon
inducer tilorone hydrochloride. Clin Immunol Immunopathol 1977; 8:204-12.
67. Santiago-Raber ML, Baccala R, Haraldsson KM, et al. Type-I interferon receptor deficiency
reduces lupus-like disease in NZB mice. J Exp Med 2003; 197:777-88.
68. Braun D, Geraldes P, Demengeot J. Type I Interferon controls the onset and severity of
autoimmune manifestations in lpr mice. J Autoimmun 2003; 20:15-25.
69. Akwa Y, Hassett DE, Eloranta ML, et al. Transgenic expression of IFNalpha in the central
nervous system of mice protects against lethal neurotropic viral infection but induces
inflammation and neurodegeneration. J Immunol 1998; 161:5016-26.
70. Guyer DR, Tiedeman J, Yannuzzi LA, et al. Interferon-associated retinopathy. Arch
Ophthalmol 1993; 111:350-6.
71. Sugano S, Yanagimoto M, Suzuki T, et al. Retinal complications with elevated circulating
plasma C5a associated with interferon-alpha therapy for chronic active hepatitis C. Am J
Gastroenterol 1994; 89:2054-6.
72. Hayasaka S, Fujii M, Yamamoto Y, Noda S, Kurome H, Sasaki M. Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving interferon alfa.
Br J Ophthalmol 1995; 79:150-2.
73. Soushi S, Kobayashi F, Obazawa H, et al. [Evaluation of risk factors of interferon-associated
retinopathy in patients with type C chronic active hepatitis]. Nippon Ganka Gakkai Zasshi
1996; 100:69-76.
74. Kawano T, Shigehira M, Uto H, et al. Retinal complications during interferon therapy for
chronic hepatitis C. Am J Gastroenterol 1996; 91:309-13.
75. Lebon P. Inhibition of herpes simplex virus type 1-induced interferon synthesis by monoclonal antibodies against viral glycoprotein D and by lysosomotropic drugs. J Gen Virol 1985;
66:2781-6.
76. Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic
lupus erythematosus blood. J Exp Med 2003; 197:711-23.
77. Chuntharapai A, Lai J, Huang X, et al. Characterization and humanization of a monoclonal
antibody that neutralizes human leukocyte interferon: a candidate therapeutic for IDDM
and SLE. Cytokine 2001; 15:250-60.
78. Han CS, Chen Y, Ezashi T, Roberts RM. Antiviral activities of the soluble extracellular
domains of type I interferon receptors. Proc Natl Acad Sci USA 2001; 98:6138-43.

©

20

08

LA

ND

ES

BIO

SC

IEN
CE

.D

ON

14. Barnes MH, Spacciapoli P, Li DH, Brown NC. The 3'–5' exonuclease site of DNA polymerase III from gram-positive bacteria: definition of a novel motif structure. Gene 1995;
165:45-50.
15. Strauss BS, Sagher D, Acharya S. Role of proofreading and mismatch repair in maintaining
the stability of nucleotide repeats in DNA. Nucleic Acids Res 1997; 25:806-13.
16. Taft-Benz SA, Schaaper RM. Mutational analysis of the 3'→5' proofreading exonuclease of
Escherichia coli DNA polymerase III. Nucleic Acids Res 1998; 26:4005-11.
17. de Silva U, Choudhury S, Bailey SL, Harvey S, Perrino FW, Hollis T. The crystal structure
of TREX1 explains the 3' nucleotide specificity and reveals a polyproline II helix for protein
partnering. J Biol Chem 2007; 282:10537-43.
18. Brucet M, Querol-Audi J, Serra M, et al. Structure of the dimeric exonuclease TREX1 in
complex with DNA displays a proline-rich binding site for WW domains. J Biol Chem
2007.
19. Zarrinpar A, Bhattacharyya RP, Lim WA. The structure and function of proline recognition
domains. Sci STKE 2003; 2003:8.
20. Bebenek K, Matsuda T, Masutani C, Hanaoka F, Kunkel TA. Proofreading of DNA polymerase eta-dependent replication errors. J Biol Chem 2001; 276:2317-20.
21. Mazur DJ, Perrino FW. Structure and expression of the TREX1 and TREX2 3’→5’ exonuclease genes. J Biol Chem 2001; 276:14718-27.
22. Morita M, Stamp G, Robins P, et al. Gene-targeted mice lacking the Trex1 (DNase III)
3’→5’ DNA exonuclease develop inflammatory myocarditis. Mol Cell Biol 2004; 24:671927.
23. Chowdhury D, Beresford PJ, Zhu P, et al. The exonuclease TREX1 is in the SET complex
and acts in concert with NM23-H1 to degrade DNA during granzyme A-mediated cell
death. Mol Cell 2006; 23:133-42.
24. Yang YG, Lindahl T, Barnes DE. Trex1 Exonuclease Degrades ssDNA to Prevent Chronic
Checkpoint Activation and Autoimmune Disease. Cell 2007; 131:873-86.
25. Coscoy L, Raulet DH. DNA mismanagement leads to immune system oversight. Cell 2007;
131:836-8.
26. Chen MJ, Ma SM, Dumitrache LC, Hasty P. Biochemical and cellular characteristics of the
3'→5' exonuclease TREX2. Nucleic Acids Res 2007; 35:2682-94.
27. Aicardi J, Goutieres F. A progressive familial encephalopathy in infancy with calcifications of
the basal ganglia and chronic cerebrospinal fluid lymphocytosis. Ann Neurol 1984; 15:49-54.
28. Goutieres F. Aicardi-Goutieres syndrome. Brain Dev 2005; 27:201-6.
29. Goutieres F, Aicardi J, Barth PG, Lebon P. Aicardi-Goutieres syndrome: an update and
results of interferon-alpha studies. Ann Neurol 1998; 44:900-7.
30. Burn J, Wickramasinghe HT, Harding B, Baraitser M. A syndrome with intracranial calcification and microcephaly in two sibs, resembling intrauterine infection. Clin Genet 1986;
30:112-6.
31. Reardon W, Hockey A, Silberstein P, et al. Autosomal recessive congenital intrauterine
infecction-like syndrome of microcephaly, intracranial calcification and CNS disease.
American Journal Medical Genetics 1994; 52:58-65.
32. Black DN, Watters GV, Andermann E, et al. Encephalitis among Cree children in northern
Quebec. J Med Genet 1988; 40:183-7.
33. Sanchis A, Cervero L, Bataller A, et al. Genetic syndromes mimic congenital infections. J
Pediatr 2005; 146:701-5.
34. Crow YJ, Black DN, Ali M, et al. Cree encephalitis is allelic with Aicardi-Goutieres syndrome: implications for the pathogenesis of disorders of interferon alpha metabolism. J Med
Genet 2003; 40:183-7.
35. Dale RC, Tang SP, Heckmatt JZ, Tatnall FM. Familial systemic lupus erythematosus and
congenital infection-like syndrome. Neuropediatrics 2000; 31:155-8.
36. Rasmussen M, Skullerud K, Bakke SJ, Lebon P, Jahnsen FL. Cerebral thrombotic microangiopathy and antiphospholipid antibodies in Aicardi-Goutieres syndrome—report of two
sisters. Neuropediatrics 2005; 36:40-4.
37. De Laet C, Goyens P, Christophe C, Ferster A, Mascart F, Dan B. Phenotypic overlap between infantile systemic lupus erythematosus and Aicardi-Goutieres syndrome.
Neuropediatrics 2005; 36:399-402.
38. Lebon P, Lenoir GR, Fischer A, Lagrue A. Synthesis of intrathecal interferon in systemic lupus erythematosus with neurological complications. Br Med J (Clin Res Ed) 1983;
287:1165-7.
39. Crow YJ, Leitch A, Hayward BE, et al. Mutations in genes encoding ribonuclease H2
subunits cause Aicardi-Goutières syndrome and mimic congenital viral brain infection. Nat
Genet 2006; 38:910-6.
40. Frank P, Braunshofer-Reiter C, Wintersberger U, Grimm R, Busen W. Cloning of the
cDNA encoding the large subunit of human RNase HI, a homologue of the prokaryotic
RNase HII. Proc Natl Acad Sci USA 1998; 95:12872-7.
41. Eder PS, Walder JA. Ribonuclease H from K562 human erythroleukemia cells. Purification,
characterization and substrate specificity. J Biol Chem 1991; 266:6472-9.
42. Rice G, Patrick T, Parmar R, et al. Clinical and molecular phenotype of Aicardi-Goutieres
syndrome. American Journal of Human Genetics 2007; 81:713-25.
43. Lee-Kirsch MA, Chowdhury D, Harvey S, et al. A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus. J Mol Med
2007; 85:531-7.
44. Millard LG, Rowell NR. Chilblain lupus erythematosus (Hutchinson). A clinical and laboratory study of 17 patients. Br J Dermatol 1978; 98:497-506.
45. Grand MG, Kaine J, Fulling K, et al. Cerebroretinal vasculopathy: A new hereditary syndrome. Ophthalmology 1988; 95:649-59.
46. Gutmann DH, Fischbeck KH, Sergott RC. Hereditary retinal vasculopathy with cerebral
white matter lesions. Am J Med Genet 1989; 34:217-20.

www.landesbioscience.com

Cell Cycle

1725

